🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our lineup at hashtag#SNIS2024 is PAC’d. Visit us at booth #109 for some healthy competition. Test your steering skills at PAC-MAN with a neurovascular twist, and learn more about our other exciting activities throughout the week. See you soon! 🏔 #RapidMedical #DRIVEWIRE

LIVE from the 2024 SNIS Annual Meeting, we’re pleased to announce the first cases performed by Dr. Shahram Majidi following FDA clearance of DRIVEWIRE 24 in the US. Visit booth 109 to learn more & top the Drive to Survive leaderboard! Shahram Majidi, MD businesswire.com/news/home/2024…

SNIS Meeting Attendees: On the heels of DRIVEWIRE™ 24’s FDA clearance, join us and Dr. Shahram Majidi, MD outside of the exhibit hall on Bartolin Patio at 2pm for a Grand Prix Event you won’t want to miss! #DW24 at #SNIS24 #ReshapeNavigation

That’s a wrap on a great #SNIS2024! From gaining FDA clearance on DRIVEWIRE 24, to presenting exciting new evidence with COMANECI - thank you to SNIS Info and our physician partners for your support and enthusiasm throughout the week Jason Davies, MD,PhD Shahram Majidi, MD Johannes

FINAL RESULTS show high occlusion rates of the COMANECI™️ embolization assist device for intracranial aneurysm treatment. The #SUCCESSStudy assesses the safety and efficacy of COMANECI in the U.S. Data indicates: • 95% (P=0.05) RR I & II at 6 months • Highest occlusion rates

Recent data from the #SUCCESSStudy indicate a favorable safety profile, high effectiveness, and low complication rates with the COMANECI™ embolization assist device. Results reported: ✅ Zero symptomatic thromboembolic events (across all ruptured and unruptured cases) compared

Our CEO and co-founder, Ronen Eckhouse, recently presented at the Future of Healthcare Investment Forum, hosted by the London Stock Exchange. With a spotlight on our unique portfolio, Mr. Eckhouse emphasized the global need to expand effective stroke care, and how our novel

Marseille, here we come! We look forward to an exciting #ESMINT2024. Join us throughout the week: - Visit booth #19 to learn more about our latest technology, new clinical data, and to test your tailored thrombectomy skills at the TIGERTRIEVER™ Simulator. - Stop by the e-Poster

Live from #ESMINT2024 – Rapid Medical announces completion of the interim safety analysis of the DISTALS Study with TIGERTRIEVER 13 for medium vessel occlusions. “We are pleased that the DSMB found that the safety profile of TIGERTRIEVER 13 allows us to continue randomization.

#ESMINT2024 is underway! Stop by booth #19 to meet the team and our latest addition to the TIGER family. ESMINT Society #TIGERTRIEVER #stroke #thrombectomy #neurointervention #RapidMedical

Congratulations to Dr. Jeremy Rempel (Alberta, Canada) for completing the first TIGERTIREVER™️ 25 case worldwide! Designed to handle large clots, TIGERTRIEVER 25 is equipped with the strength and length vital for optimal integration and retrieval. - Carotid T occlusion extending

Excellent results and fast procedure times have been published utilizing TIGERTRIEVER™️’s active technology. In a guide compiled by 26 leading clinicians, learn more about how operator-controlled adjustability can accelerate thrombectomy procedures for better patient outcomes.

📢 Calling all Fellows! Join us on November 6-7th for a Rapid Medical Fellows Course in Park Ridge, IL. Gain insight from leading experts, Drs. Edgar Samaniego and Hamad Farhat, and get hands-on with TIGERTRIEVER™, COMANECI™, and NUMEN™ for stroke & aneurysm treatment. Space

DGNR 2024 Attendees! Stop by booth #H06 to meet the newest member of the TIGER family, and join us on Friday at 10:00 as Dr. Johannes Hensler (UKSH Campus Kiel) presents, “Multi-center Study To Assess Effectiveness Of The Comaneci Device In The Treatment Of Symptomatic Cerebral